Alnylam Pharmaceuticals (ALNY) Stock Chart & Stock Price History $435.00 -3.93 (-0.90%) Closing price 04:00 PM EasternExtended Trading$437.25 +2.25 (+0.52%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Alnylam Pharmaceuticals Stock Price Performance The Alnylam Pharmaceuticals (ALNY) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has increased 61.40%, with a year-to-date return of 84.86%. In the past month, the stock has increased 38.12%, reflecting recent market activity. As of the latest close, Alnylam Pharmaceuticals traded at $438.93 with a market cap of $57.53 billion and volume of 901,269 shares. Five years ago, the stock traded at $136.61, representing a 218.42% increase over that period. At the time, it had a market cap of $16.18 billion and a volume of 469,283 shares. Receive ALNY Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance+1.60%1 Month Performance+38.12%3 Month Performance+72.62%Year-To-Date Performance+84.86%1 Year Performance+61.40%5 Year Performance+218.42% ALNY Stock Chart for Monday, August, 11, 2025 ALNY Chart by TradingView Alnylam Pharmaceuticals Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization08/11/2025$438.93$435.00-0.90%$445.20$426.19988,636 shs$57.02 billion08/08/2025$435.10$438.93+0.88%$439.36$427.66901,269 shs$57.53 billion08/07/2025$428.14$435.10+1.63%$436.77$425.811.15 million shs$57.03 billion08/06/2025$418.91$428.14+2.20%$428.69$415.001.18 million shs$56.12 billion08/05/2025$419.55$418.91-0.15%$426.76$410.491.81 million shs$54.91 billion08/04/2025$401.80$419.55+4.42%$422.64$398.911.46 million shs$54.99 billion08/01/2025$392.24$401.80+2.44%$401.80$382.191.78 million shs$52.39 billion07/31/2025$339.80$392.24+15.43%$402.43$350.003.35 million shs$51.14 billion07/30/2025$330.55$339.80+2.80%$345.98$333.032.05 million shs$44.31 billion07/29/2025$324.79$330.55+1.77%$331.06$323.74862,470 shs$43.10 billion Get the Latest News and Ratings for ALNY and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 07/28/2025$328.81$324.79-1.22%$331.43$324.781.03 million shs$42.35 billion07/25/2025$328.00$328.81+0.25%$331.50$324.55666,674 shs$42.87 billion07/24/2025$325.64$328.00+0.72%$332.19$324.30672,389 shs$42.77 billion07/23/2025$325.28$325.64+0.11%$329.34$322.30912,188 shs$42.46 billion07/22/2025$320.52$325.28+1.49%$326.30$320.181.27 million shs$42.41 billion07/21/2025$320.53$320.520.00%$328.70$320.26744,525 shs$41.79 billion07/18/2025$324.69$320.53-1.28%$325.62$317.88581,322 shs$41.79 billion07/17/2025$322.81$324.69+0.58%$329.87$321.06744,559 shs$42.34 billion07/16/2025$311.12$322.81+3.76%$323.41$311.261.23 million shs$42.09 billion07/15/2025$315.75$311.12-1.47%$316.90$309.57927,235 shs$40.57 billion07/14/2025$314.94$315.75+0.26%$319.18$313.76629,558 shs$41.17 billion07/11/2025$322.64$314.94-2.39%$321.12$312.961.08 million shs$41.07 billion07/10/2025$320.87$322.64+0.55%$324.82$319.15489,398 shs$42.07 billion Related Companies Amgen Stock Price Chart Gilead Sciences Stock Price Chart Vertex Pharmaceuticals Stock Price Chart Regeneron Pharmaceuticals Stock Price Chart Biogen Stock Price Chart Incyte Stock Price Chart United Therapeutics Stock Price Chart Neurocrine Biosciences Stock Price Chart BioMarin Pharmaceutical Stock Price Chart Exelixis Stock Price Chart Receive ALNY Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:ALNY) was last updated on 8/11/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alnylam Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alnylam Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access